| abstract |
The present disclosure relates to purine compounds of formula (I) or formula (II) (see formula I) (see formula II) or tautomers, polymorphs, stereoisomers, solvates or pharmaceutically acceptable salts thereof, where substituents arc as defined herein, as well as pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by thereof as A2B adenosine receptor antagonists. The compounds of the present disclosure may be useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by the mediation of adenosine A2B receptor. The present disclosure also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them. |